| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/10/2004 | US20040109859 Method for the treatment of multiple sclerosis |
| 06/10/2004 | US20040109847 Treatment and prophylaxis with 4-1BB-binding agents |
| 06/10/2004 | US20040109846 Restoring cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| 06/10/2004 | US20040108086 Using Ecteinascidin- 743 drug alone or as part of synergistic mixture |
| 06/10/2004 | CA2507887A1 Nucleotide based medicament and method of use for treatment of conditions in humans |
| 06/10/2004 | CA2507266A1 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor |
| 06/10/2004 | CA2506984A1 Polyphosphazene immunocstimulants |
| 06/10/2004 | CA2506948A1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 06/10/2004 | CA2506607A1 Use of the corticoliberin-urocortin system in the treatment of inflammatory diseases |
| 06/10/2004 | CA2503246A1 Compositions and methods for diagnosing and treating mood disorders |
| 06/10/2004 | CA2485950A1 Methods for cohort selection and longevity studies |
| 06/09/2004 | EP1426053A1 Use of amphiphilic lipids for reducing tumor metastasis |
| 06/09/2004 | EP1426052A1 Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof |
| 06/09/2004 | EP1426051A1 Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy |
| 06/09/2004 | EP1426050A1 Jnk inhibitors |
| 06/09/2004 | EP1426048A2 Treating hypertriglyceridemia with RXR agonists in combination with a PPARgamma agonist |
| 06/09/2004 | EP1426044A1 Use of esters of L-carnitine or alkanoyl L-carnitines as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 06/09/2004 | EP1425587A2 Method for identifying anti-inflammatory drugs |
| 06/09/2004 | EP1425413A2 Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
| 06/09/2004 | EP1425399A2 Combinatorial methods for inducing cancer cell death |
| 06/09/2004 | EP1425390A2 Materials and methods to promote repair of nerve tissue |
| 06/09/2004 | EP1425389A2 Human antibodies specific for interleukin 15 (il-15) |
| 06/09/2004 | EP1425289A2 Novel nucleic acid and polypeptide molecules |
| 06/09/2004 | EP1425284A2 Furo- and thienopyrimidine derivatives as angiogenesis inhibitors |
| 06/09/2004 | EP1425264A1 C2-disubstituted indane-1-ol systems, method for their production and their use as medicaments |
| 06/09/2004 | EP1425043A1 Method of increasing the presence of glutathione in cells |
| 06/09/2004 | EP1425042A1 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| 06/09/2004 | EP1425035A1 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 06/09/2004 | EP1425034A1 Method for treating coumarin-induced hemorrhage |
| 06/09/2004 | EP1425031A2 Hdl for the treatment of stroke and other ischemic conditions |
| 06/09/2004 | EP1425030A2 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof |
| 06/09/2004 | EP1425029A1 Peptidomimetics of biologically active metallopeptides |
| 06/09/2004 | EP1425028A2 Use of il-18 inhibitors for the treatement or prevention of sepsis |
| 06/09/2004 | EP1425021A1 Physiological method of improving vision |
| 06/09/2004 | EP1425018A1 Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof |
| 06/09/2004 | EP1425017A1 Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| 06/09/2004 | EP1425014A1 Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators |
| 06/09/2004 | EP1425002A1 Aryloxypropylamines as chemosensitizing agents in the treatment of cancer |
| 06/09/2004 | EP1425001A1 Phenethanolamine derivatives for treatment of respiratory diseases |
| 06/09/2004 | EP1424996A1 Method for the production of inhalation powders |
| 06/09/2004 | EP1424971A1 Eustachian tube stent |
| 06/09/2004 | EP1424957A2 Microfabricated nanopore device for sustained release of therapeutic agent |
| 06/09/2004 | EP1424898A1 Treatment of cancers by inhalation of stable platinum-containing formulations |
| 06/09/2004 | EP1424889A2 Method for treating lung cancers |
| 06/09/2004 | EP0934081B1 Antineoplastic conjugates of albumin |
| 06/09/2004 | DE20220902U1 Neuer Filmüberzug New film coating |
| 06/09/2004 | DE10320633A1 Verfahren zur Identifizierung einer möglichen Modifikation von mindestens einem biologischen Parameter unter Verwendung von lebenden Zellen, die einem Reiz ausgesetzt wurden, und lebenden Zellen, die nicht diesem Reiz ausgesetzt wurden A method of identifying a possible modification of at least one biological parameter using living cells that were exposed to a stimulus, and living cells that were not exposed to this stimulus |
| 06/09/2004 | DE10320603A1 Verfahren zum Testen der Aktivität einer möglichen wirksamen Substanz, die die enzymatische Aktivität der Phospholipase A2 hemmen kann A method for testing the activity of a possible active substance which inhibit the enzymatic activity of phospholipase A2 can |
| 06/09/2004 | DE10320602A1 Verfahren zur Identifizierung einer möglichen Modifikation von mindestens einem biologischen Parameter unter Verwendung von jungen und alten lebenden Zellen A method for identifying a possible modification of at least one biological parameters using young and old living cells |
| 06/09/2004 | DE10256184A1 Reducing hepatotoxicity of microsomal triglyceride transfer protein inhibitors, used e.g. in treatment of hyperlipemia, atherosclerosis or diabetes, by co-administration with fibrate |
| 06/09/2004 | DE10254584A1 Verwendung von mittelkettigen Triglyceriden (MCT) zur ernährungsphysiologischen Optimierung des Fettsäurenspektrums in einem diätetischen Lebensmittel für Diabetiker The use of medium chain triglycerides (MCT) to optimize the nutritional fatty acids spectrum in a dietetic foods for diabetics |
| 06/09/2004 | CN1503684A Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
| 06/09/2004 | CN1503679A Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof |
| 06/09/2004 | CN1503677A Use of LP 82 to treat hematopoietic disorders |
| 06/09/2004 | CN1503671A Agent for topical ophthalmic treatment of ocular inflammatory diseases |
| 06/09/2004 | CN1503663A Film coating |
| 06/09/2004 | CN1502697A Alzhimer's disease secretase |
| 06/09/2004 | CN1502696A Alzheimer's disease secretase |
| 06/09/2004 | CN1502692A Alzheimer's disease secretase |
| 06/09/2004 | CN1502370A Composition for cooperative therapy and method thereof |
| 06/09/2004 | CN1502331A Anti-angiogenic compositions and methods of use |
| 06/09/2004 | CN1152962C Antiangiogenic peptides derived from plasminogen, its coded polynucleotide and method of inhibiting vascularization |
| 06/09/2004 | CN1152717C Oral medicinal preparation |
| 06/09/2004 | CN1152685C Usage of endothelin receptor agonist in preparation of medicine for treating obesity |
| 06/09/2004 | CN1152682C Usage of histamine receptor antagonists composition in preparation of medicine for treating |
| 06/09/2004 | CN1152680C Pharmaceutical composition containing liphase inhibitors and chitosan |
| 06/09/2004 | CN1152668C Glucose-contg. preparation |
| 06/08/2004 | US6747149 Glucamine salts for treating hepatitis virus infections |
| 06/08/2004 | US6747134 Antibody immunologically reactive with serine protease EOS |
| 06/08/2004 | US6747064 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 06/08/2004 | US6747063 Augmenting actions of camp in an effector system while reducing camp action in a nociceptive system comprising application of one or more forms of nitrogen oxide or carbon monoxide to a site wherein camp exists |
| 06/08/2004 | US6747061 N-substituted dithiocarbamates for the treatment of biological disorders |
| 06/08/2004 | US6747059 Composition for, and methods of, anti-platelet therapy |
| 06/08/2004 | US6747052 Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 06/08/2004 | US6747049 Oxazole derivatives |
| 06/08/2004 | US6747036 Use of nucleoside analogues (cytosine or 5-fluorocytosine containing compound) useful for acute or chronic myelogenous leukemia |
| 06/08/2004 | US6747028 1,2-substituted benzimidazoles having antiviral activity |
| 06/08/2004 | US6747020 Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor |
| 06/08/2004 | US6747017 Endopeptidase inhibitor |
| 06/08/2004 | US6747008 Methods for treating and preventing alopecia |
| 06/08/2004 | US6747007 Cationic, polyphemusin-like peptides |
| 06/08/2004 | US6747005 Determining importin alpha activities in presence and absence of camp-response element binding protein which acetylates importin alpha to determine effect on activities, comparing effect in presence and absence of test compound |
| 06/08/2004 | US6747004 Contacting embryonic forebrain cells in vitro with amount of endometrial bleeding associated factor protein having specified amino acid sequence effective to induce proliferation of forebrain cells |
| 06/08/2004 | US6746773 Implant with coating of copolymer of vinylidenefluoride (vdf) and/or tetrafluoroethylene (tfe) with another monomer in amounts effective to reduce thrombosis and/or restenosis when such stents are used in, e.g. angioplasty procedures |
| 06/08/2004 | US6746678 Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| 06/08/2004 | CA2201358C Pharmaceutical composition |
| 06/06/2004 | CA2413705A1 Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
| 06/04/2004 | CA2449417A1 Methods for identifiying compounds for regulating cardiac dysfunction |
| 06/03/2004 | WO2004046331A2 2’-branched nucleosides and flaviviridae mutation |
| 06/03/2004 | WO2004046309A2 Methods for inhibiting viral replication in vivo |
| 06/03/2004 | WO2004046211A1 Polymeric boronic acid derivatives as lipase inhibitors |
| 06/03/2004 | WO2004046115A1 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors |
| 06/03/2004 | WO2004046070A2 Modulation of proteins by phenolic compoudns |
| 06/03/2004 | WO2004045718A2 Treatment of cognitive dysfunctions' |
| 06/03/2004 | WO2004045679A1 Peritoneal dialysis method |
| 06/03/2004 | WO2004045644A1 REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND β-BLOCKER |
| 06/03/2004 | WO2004045642A1 Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics |
| 06/03/2004 | WO2004045640A1 Gastrin compositions and formulations, and methods of use and preparation |
| 06/03/2004 | WO2004045635A1 Muslce building preparation |
| 06/03/2004 | WO2004045620A1 Use of selective progesterone receptor modulators for the treatment of androgen deficiency |